Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) have been given a consensus recommendation of “Moderate Buy” by the eight analysts that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and five have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $13.70.

Several equities analysts have commented on VNDA shares. HC Wainwright decreased their target price on shares of Vanda Pharmaceuticals from $21.00 to $20.00 and set a “buy” rating on the stock in a report on Monday. B. Riley Financial reaffirmed a “buy” rating and issued a $12.00 target price (down from $17.00) on shares of Vanda Pharmaceuticals in a report on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Friday, July 17th. Finally, Wall Street Zen lowered Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th.

Vanda Pharmaceuticals Price Performance

Vanda Pharmaceuticals stock opened at $5.19 on Thursday. Vanda Pharmaceuticals has a 12 month low of $4.27 and a 12 month high of $9.94. The stock’s 50 day moving average is $5.71 and its 200-day moving average is $6.69. The company has a current ratio of 1.61, a quick ratio of 1.60 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $313.80 million, a price-to-earnings ratio of -1.12 and a beta of 0.64.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.46). The firm had revenue of $50.53 million for the quarter, compared to analyst estimates of $61.92 million. Vanda Pharmaceuticals had a negative return on equity of 49.81% and a negative net margin of 127.41%. Equities research analysts expect that Vanda Pharmaceuticals will post -3 EPS for the current year.

Institutional Trading of Vanda Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VNDA. Quantbot Technologies LP bought a new stake in shares of Vanda Pharmaceuticals in the 2nd quarter worth approximately $29,000. Ieq Capital LLC purchased a new position in shares of Vanda Pharmaceuticals during the 2nd quarter valued at $1,731,000. Allworth Financial LP purchased a new position in Vanda Pharmaceuticals during the second quarter worth about $43,000. BlackRock Inc. bought a new position in shares of Vanda Pharmaceuticals in the second quarter worth approximately $46,841,000. Finally, Pallas Capital Advisors LLC bought a new position in shares of Vanda Pharmaceuticals in the 2nd quarter worth $114,000. 88.14% of the stock is owned by institutional investors.

Vanda Pharmaceuticals News Roundup

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: Analyst ratings remain bullish: HC Wainwright maintained a “Buy” rating and a $20 price target, while B. Riley Financial reiterated its “Buy” recommendation. These targets imply significant upside from recent trading levels. B. Riley Financial Reiterates Buy Rating for Vanda Pharmaceuticals
• Positive Sentiment: Psoriasis pipeline visibility: Vanda was included among psoriasis drug stocks to watch during Psoriasis Awareness Month. The company’s potential exposure to psoriasis therapies could provide an additional growth opportunity if its programs advance successfully. 4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
• Neutral Sentiment: Short-interest data shows no meaningful bearish positioning: Reported short interest was zero shares, with a zero-day days-to-cover ratio. However, the reported increase is mathematically invalid because the prior period also showed zero shares, making this data of limited investment value.
• Negative Sentiment: HC Wainwright significantly lowered earnings forecasts: The firm cut its FY2026 EPS estimate to a loss of $3.03 from a loss of $1.98 and reduced its FY2027 estimate to a loss of $0.94 from a loss of $0.36. Quarterly estimates were also lowered across Q3 2026 through Q4 2027, including Q3 2026 EPS of negative $0.61 and Q4 2026 EPS of negative $0.57.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.